Recombinant lnterleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation: A case report of cardiovascular toxicity with serial echocardiographic evaluation

D. Schechter; A. Nagler; A. Ackerstein; H. Nassar; D. Admon; E. Naparstek; A. J. Rein

doi:10.1159/000174999

Recombinant lnterleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation: A case report of cardiovascular toxicity with serial echocardiographic evaluation

D. Schechter^*, A. Nagler, A. Ackerstein, H. Nassar, D. Admon, E. Naparstek, A. J. Rein

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

The most serious side effects of recombinant interleukin-2 (rIL-2) and recombinant interferon-a (rIFNa) immunotherapy are cardiovascular disturbances, including systemic hypotension. left-ventricular dysfunction and pulmonary edema. We present a 25-year-old female who developed reversible cardiogenic shock during intermediate dose rIL-2 and low dose rIFNa therapy. Rapid clinical improvement occurred after intravenous fluid and dopamine support. A serial echocardiography evaluation, which has not been described previously in this setting, is reported.

Original language	English
Pages (from-to)	168-171
Number of pages	4
Journal	Cardiology
Volume	80
Issue number	3-4
DOIs	https://doi.org/10.1159/000174999
State	Published - 1992
Externally published	Yes

Keywords

Autologous bone marrow
Recombinant intcrferon-α cardiotoxicity
Recombinant interlcukin-2
Transplantation

Access to Document

10.1159/000174999

Cite this

@article{52d139e33ad54af39d751bf834ad7e1e,

title = "Recombinant lnterleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation: A case report of cardiovascular toxicity with serial echocardiographic evaluation",

abstract = "The most serious side effects of recombinant interleukin-2 (rIL-2) and recombinant interferon-a (rIFNa) immunotherapy are cardiovascular disturbances, including systemic hypotension. left-ventricular dysfunction and pulmonary edema. We present a 25-year-old female who developed reversible cardiogenic shock during intermediate dose rIL-2 and low dose rIFNa therapy. Rapid clinical improvement occurred after intravenous fluid and dopamine support. A serial echocardiography evaluation, which has not been described previously in this setting, is reported.",

keywords = "Autologous bone marrow, Recombinant intcrferon-α cardiotoxicity, Recombinant interlcukin-2, Transplantation",

author = "D. Schechter and A. Nagler and A. Ackerstein and H. Nassar and D. Admon and E. Naparstek and Rein, {A. J.}",

year = "1992",

doi = "10.1159/000174999",

language = "אנגלית",

volume = "80",

pages = "168--171",

journal = "Cardiology",

issn = "0008-6312",

publisher = "S. Karger AG",

number = "3-4",

}

TY - JOUR

T1 - Recombinant lnterleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation

T2 - A case report of cardiovascular toxicity with serial echocardiographic evaluation

AU - Schechter, D.

AU - Nagler, A.

AU - Ackerstein, A.

AU - Nassar, H.

AU - Admon, D.

AU - Naparstek, E.

AU - Rein, A. J.

PY - 1992

Y1 - 1992

N2 - The most serious side effects of recombinant interleukin-2 (rIL-2) and recombinant interferon-a (rIFNa) immunotherapy are cardiovascular disturbances, including systemic hypotension. left-ventricular dysfunction and pulmonary edema. We present a 25-year-old female who developed reversible cardiogenic shock during intermediate dose rIL-2 and low dose rIFNa therapy. Rapid clinical improvement occurred after intravenous fluid and dopamine support. A serial echocardiography evaluation, which has not been described previously in this setting, is reported.

AB - The most serious side effects of recombinant interleukin-2 (rIL-2) and recombinant interferon-a (rIFNa) immunotherapy are cardiovascular disturbances, including systemic hypotension. left-ventricular dysfunction and pulmonary edema. We present a 25-year-old female who developed reversible cardiogenic shock during intermediate dose rIL-2 and low dose rIFNa therapy. Rapid clinical improvement occurred after intravenous fluid and dopamine support. A serial echocardiography evaluation, which has not been described previously in this setting, is reported.

KW - Autologous bone marrow

KW - Recombinant intcrferon-α cardiotoxicity

KW - Recombinant interlcukin-2

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0026736027&partnerID=8YFLogxK

U2 - 10.1159/000174999

DO - 10.1159/000174999

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0026736027

SN - 0008-6312

VL - 80

SP - 168

EP - 171

JO - Cardiology

JF - Cardiology

IS - 3-4

ER -

Recombinant lnterleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation: A case report of cardiovascular toxicity with serial echocardiographic evaluation

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this